Two top Las Vegas cardiologists, Sean Ameli, M.D., and Berge Dadourian, M.D., announced that the Ameli | Dadourian Heart Center has transitioned to a concierge cardiology practice. Located in Tivoli Village in Summerlin, the Ameli | Dadourian Heart Center offers access to high-quality cardiology care featuring same- or next-day appointments, phone calls answered by friendly staff and ongoing preventative educational services.

HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been completed. ENDURANCE2 is the largest destination therapy clinical trial of a ventricular assist device conducted to date and is designed to evaluate patients implanted with the HeartWare Ventricular Assist Device (HVAD) for long-term use as destination therapy in the United States. Data from the ENDURANCE program are expected to form the basis for a pre-market approval (PMA) application seeking approval of the HeartWare System for destination therapy.

On July 2, Cook Medical initiated a voluntary recall of 2,239 lots of beacon tip angiographic catheters. A total of 95,167 devices globally are subject to this recall. The products include specific versions and lot numbers of the Torcon NB Advantage beacon tip catheters, Royal Flush Plus beacon tip high-flow catheters and Slip-Cath beacon tip catheters.

Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early detection of cardiac arrhythmias offered by BioMonitor, and subsequent treatments, reduce the likelihood of major adverse cardiovascular events (MACE). The study will, for the first time ever, examine patients with relatively preserved left ventricular ejection fraction (LVEF > 35 percent), who have experienced acute myocardial infarction (AMI).

Boston Scientific has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related diagnostic and monitoring offerings.

Several common measures obtained from electrocardiograms (ECGs) may help clinicians determine a kidney disease patient’s risk of dying from heart disease. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), may be important for preserving kidney patients’ heart health.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now